The use of aromatase inhibitors (AIs), LHRH-α, oestrogen receptor antagonists, and other adjuvant endocrine therapies in clinical practice is the standard treatment method for ER+ BC patients. The gene discussed is CYP19A1; the disease is breast cancer.